Inspiration Healthcare Group plc (LSE:IHC) has repositioned itself as a more focused neonatal medical technology business. Its results for the 2026 financial year showed Revenue growth of 24% and a sharpened focus on neonatal care following the sale of its infusion business. The company has also raised fresh share capital, published its Annual Report and held its annual general meeting, keeping it in view among healthcare names on the FTSE AIM All Share Index.
What the Company Does
Inspiration Healthcare develops, manufactures and supplies medical technology, with a particular emphasis on products used in the care of newborn babies, such as equipment for neonatal intensive care units. It sells to hospitals in the UK, including within the NHS, and to customers internationally. The disposal of its infusion Business means the group is now more concentrated on the neonatal market, where it aims to build on its existing product portfolio and customer relationships.
Latest Developments
The company published a full-year trading update on 12 February 2026, followed by a notice of results and then its final results for the 2026 financial year. Revenue grew by 24% alongside the strategic refocus on neonatal MedTech after the infusion divestment. The company hailed a solid order Backlog as revenue jumped. Profit figures and the size of the backlog were not available at the time of writing.
On the funding side, the company set out a proposed placing and subscription to raise £2.5 million. The full terms, including the issue price, were not confirmed at the time of writing. The group has since released its annual report and notice of AGM, and the result of the AGM has been announced. The company has also granted share Options to executives. Separately, the company announced that its UK neonatal division had won a place on an NHS framework agreement, which can make it easier for hospitals to purchase its products.
Financial Picture
The combination of revenue growth, a solid order backlog and a modest share raise suggests the company is investing to support its refocused strategy while managing its balance sheet. The disposal of the infusion business will also affect reported comparisons, so investors may need to look at continuing operations when assessing performance. Dividend information was not confirmed at the time of writing.
Sector and index Context
Medical technology companies serving hospitals are influenced by healthcare budgets, procurement processes and regulatory approval timelines. Neonatal care is a specialised niche with a steady underlying need, but purchasing decisions can be lumpy, as hospitals often buy equipment in tranches. As a constituent of the FTSE AIM All Share Index, Inspiration Healthcare is one of several smaller healthcare companies quoted on London's growth market, where funding conditions have been tight in recent years.
Key Risks
Risks include the timing of hospital orders, pressure on NHS and international healthcare budgets, regulatory requirements for medical devices, and the execution of the group's narrower strategy after the divestment. The recent placing indicates that access to capital remains important, and further fundraising could dilute existing shareholders. Competition from larger medical device groups is another consideration.
What to Watch Next
Inspiration Healthcare's financial year ends in January, so a half-year update covering trading to July is a likely next milestone. Investors will watch for conversion of the order backlog into revenue, progress in the neonatal business, the use of the funds raised, and any benefits from the NHS framework agreement.



_11_18_2026_06_43_20_247880.jpg)


Please wait processing your request...